相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Understanding and improving the one and three times GDP per capita cost-effectiveness thresholds
Lisa A. Robinson et al.
HEALTH POLICY AND PLANNING (2017)
Systematic overview of cost-effectiveness thresholds in ten countries across four continents
Ruth Schwarzer et al.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2015)
The Willingness to Pay for a Quality Adjusted Life Year: A Review of the Empirical Literature
Linda Ryen et al.
HEALTH ECONOMICS (2015)
A Systematic Review of Studies Eliciting Willingness-to-Pay per Quality-Adjusted Life Year: Does It Justify CE Threshold?
Khachapon Nimdet et al.
PLOS ONE (2015)
Updating Cost-Effectiveness - The Curious Resilience of the $50,000-per-QALY Threshold
Peter J. Neumann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The Value of a QALY: Individual Willingness to Pay for Health Gains Under Risk
Ana Bobinac et al.
PHARMACOECONOMICS (2014)
Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria
Laszlo Gulacsi et al.
EUROPEAN JOURNAL OF HEALTH ECONOMICS (2014)
VALUING QALY GAINS BY APPLYING A SOCIETAL PERSPECTIVE
Ana Bobinac et al.
HEALTH ECONOMICS (2013)
Routine HIV Screening in Portugal: Clinical Impact and Cost-Effectiveness
Yazdan Yazdanpanah et al.
PLOS ONE (2013)
Estimating the willingness to pay for a quality-adjusted life year in Thailand: does the context of health gain matter?
Montarat Thavorncharoensap et al.
CLINICOECONOMICS AND OUTCOMES RESEARCH (2013)
Disentangling WTP per QALY data: different analytical approaches, different answers
Dorte Gyrd-Hansen et al.
HEALTH ECONOMICS (2012)
Healthy life expectancy for 187 countries, 1990-2010: a systematic analysis for the Global Burden Disease Study 2010
Joshua A. Salomon et al.
LANCET (2012)
Drug Reimbursement Decision-Making in Thailand, China, and South Korea
Surachat Ngorsuraches et al.
VALUE IN HEALTH (2012)
Inquiry into the Relationship between Equity Weights and the Value of the QALY
Ana Bobinac et al.
VALUE IN HEALTH (2012)
Using threshold values for cost per quality-adjusted life-year gained in healthcare decisions
Irina Cleemput et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2011)
Searchers vs surveyors in estimating the monetary value of a QALY: resolving a nasty dilemma for NICE
Rachel Baker et al.
HEALTH ECONOMICS POLICY AND LAW (2011)
INTERNATIONAL SURVEY ON WILLINGNESS-TO-PAY (WTP) FOR ONE ADDITIONAL QALY GAINED: WHAT IS THE THRESHOLD OF COST EFFECTIVENESS?
Takeru Shiroiwa et al.
HEALTH ECONOMICS (2010)
WILLINGNESS TO PAY PER QUALITY ADJUSTED LIFE-YEAR: IS ONE THRESHOLD APPLICABLE FOR ALL DECISION-MAKING?
F. L. Zhao et al.
VALUE IN HEALTH (2010)
Trying to estimate a monetary value for the QALY
Jose Luis Pinto-Prades et al.
JOURNAL OF HEALTH ECONOMICS (2009)
Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold
Scott D Grosse
Expert Review of Pharmacoeconomics & Outcomes Research (2008)
At what hip fracture risk is it cost-effective to treat?: International intervention thresholds for the treatment of osteoporosis
F. Borgstroem et al.
OSTEOPOROSIS INTERNATIONAL (2006)
Willingness to pay for a quality-adjusted life year: Implications for societal health care resource allocation
JT King et al.
MEDICAL DECISION MAKING (2005)
Use of cost-effectiveness analysis in health-care resource allocation decision-making:: How are cost-effectiveness thresholds expected to emerge?
HG Eichler et al.
VALUE IN HEALTH (2004)
Is economic evaluation in touch with society's health values?
J Coast
BRITISH MEDICAL JOURNAL (2004)
Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk
CJL Murray et al.
LANCET (2003)
The distribution problem in economic evaluation: income and the valuation of costs and consequences of health care programmes
C Donaldson et al.
HEALTH ECONOMICS (2002)
Differences in attitudes, knowledge and use of economic evaluations in decision-making in the Netherlands - The Dutch results from the EUROMET project
JEFZ Rijkom et al.
PHARMACOECONOMICS (2000)
Are pharmaceuticals cost-effective? A review of the evidence
PJ Neumann et al.
HEALTH AFFAIRS (2000)
分享论文
